Does the media favor BBNX or PLSE?

In the previous week, Beta Bionics had 4 more articles in the media than Pulse Biosciences. MarketBeat recorded 8 mentions for Beta Bionics and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.44 beat Beta Bionics' score of 0.27 indicating that Pulse Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pulse Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TMDX or BBNX?

In the previous week, TransMedics Group had 3 more articles in the media than Beta Bionics. MarketBeat recorded 11 mentions for TransMedics Group and 8 mentions for Beta Bionics. TransMedics Group's average media sentiment score of 0.97 beat Beta Bionics' score of 0.27 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beta Bionics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, BBNX or AXGN?

AxoGen has higher revenue and earnings than Beta Bionics. AxoGen is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beta Bionics $100.25M 8.68 -$73.20M -$1.65 N/A AxoGen $225.21M 11.92 -$15.70M -$0.68 N/A

Is BBNX or AXGN more profitable?

AxoGen has a net margin of -13.36% compared to Beta Bionics' net margin of -61.31%. AxoGen's return on equity of -8.90% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -61.31% -26.30% -23.25% AxoGen -13.36% -8.90% -6.47%

Does the media prefer BBNX or AXGN?

In the previous week, Beta Bionics and Beta Bionics both had 8 articles in the media. AxoGen's average media sentiment score of 1.51 beat Beta Bionics' score of 0.27 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AxoGen 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to BFLY or BBNX?

In the previous week, Beta Bionics had 3 more articles in the media than Butterfly Network. MarketBeat recorded 8 mentions for Beta Bionics and 5 mentions for Butterfly Network. Butterfly Network's average media sentiment score of 1.11 beat Beta Bionics' score of 0.27 indicating that Butterfly Network is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beta Bionics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, BBNX or ATRC?

AtriCure has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beta Bionics $100.25M 8.68 -$73.20M -$1.65 N/A AtriCure $534.53M 4.63 -$11.45M $0.21 231.81

Is BBNX or ATRC more profitable?

AtriCure has a net margin of 1.85% compared to Beta Bionics' net margin of -61.31%. AtriCure's return on equity of 2.34% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -61.31% -26.30% -23.25% AtriCure 1.85% 2.34% 1.77%

Does the media prefer BBNX or ATRC?

In the previous week, AtriCure had 4 more articles in the media than Beta Bionics. MarketBeat recorded 12 mentions for AtriCure and 8 mentions for Beta Bionics. AtriCure's average media sentiment score of 1.31 beat Beta Bionics' score of 0.27 indicating that AtriCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AtriCure 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Beta Bionics (BBNX) Competitors

$19.34 -0.39 (-1.98%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$19.33 -0.01 (-0.05%)

As of 08/25/2026 04:38 PM Eastern

Compare

BBNX vs. PLSE, TMDX, AXGN, BFLY, and ATRC

Should you buy Beta Bionics stock or one of its competitors? Beta Bionics's main competitors and comparable companies include Pulse Biosciences (PLSE), TransMedics Group (TMDX), AxoGen (AXGN), Butterfly Network (BFLY), and AtriCure (ATRC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Beta Bionics compare to Pulse Biosciences?

Beta Bionics (NASDAQ:BBNX) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Beta Bionics has a net margin of -61.31% compared to Pulse Biosciences' net margin of -6,755.78%. Beta Bionics' return on equity of -26.30% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-61.31%	-26.30%	-23.25%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

Pulse Biosciences has lower revenue, but higher earnings than Beta Bionics. Pulse Biosciences is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	8.68	-$73.20M	-$1.65	N/A
Pulse Biosciences	$350K	9,689.40	-$72.78M	-$1.18	N/A

Beta Bionics has a beta of 3.13, indicating that its stock price is 213% more volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

Beta Bionics presently has a consensus price target of $20.10, indicating a potential upside of 3.93%. Pulse Biosciences has a consensus price target of $45.25, indicating a potential downside of 7.65%. Given Beta Bionics' higher possible upside, analysts clearly believe Beta Bionics is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Beta Bionics had 4 more articles in the media than Pulse Biosciences. MarketBeat recorded 8 mentions for Beta Bionics and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.44 beat Beta Bionics' score of 0.27 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulse Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

77.0% of Pulse Biosciences shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Beta Bionics beats Pulse Biosciences on 9 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and Beta Bionics (NASDAQ:BBNX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

In the previous week, TransMedics Group had 3 more articles in the media than Beta Bionics. MarketBeat recorded 11 mentions for TransMedics Group and 8 mentions for Beta Bionics. TransMedics Group's average media sentiment score of 0.97 beat Beta Bionics' score of 0.27 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beta Bionics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TransMedics Group presently has a consensus target price of $124.18, indicating a potential upside of 32.67%. Beta Bionics has a consensus target price of $20.10, indicating a potential upside of 3.93%. Given TransMedics Group's higher possible upside, equities analysts plainly believe TransMedics Group is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

TransMedics Group has a net margin of 22.69% compared to Beta Bionics' net margin of -61.31%. TransMedics Group's return on equity of 15.88% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
Beta Bionics	-61.31%	-26.30%	-23.25%

TransMedics Group has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.13, meaning that its share price is 213% more volatile than the broader market.

TransMedics Group has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	5.34	$190.29M	$3.89	24.06
Beta Bionics	$100.25M	8.68	-$73.20M	-$1.65	N/A

99.7% of TransMedics Group shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Comparatively, 5.3% of Beta Bionics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

TransMedics Group beats Beta Bionics on 12 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to AxoGen?

Beta Bionics (NASDAQ:BBNX) and AxoGen (NASDAQ:AXGN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Beta Bionics has a beta of 3.13, suggesting that its share price is 213% more volatile than the broader market. Comparatively, AxoGen has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

AxoGen has higher revenue and earnings than Beta Bionics. AxoGen is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	8.68	-$73.20M	-$1.65	N/A
AxoGen	$225.21M	11.92	-$15.70M	-$0.68	N/A

Beta Bionics currently has a consensus target price of $20.10, indicating a potential upside of 3.93%. AxoGen has a consensus target price of $51.00, indicating a potential upside of 2.14%. Given Beta Bionics' higher possible upside, analysts clearly believe Beta Bionics is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Beta Bionics and Beta Bionics both had 8 articles in the media. AxoGen's average media sentiment score of 1.51 beat Beta Bionics' score of 0.27 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AxoGen	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

80.3% of AxoGen shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by insiders. Comparatively, 2.4% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AxoGen has a net margin of -13.36% compared to Beta Bionics' net margin of -61.31%. AxoGen's return on equity of -8.90% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-61.31%	-26.30%	-23.25%
AxoGen	-13.36%	-8.90%	-6.47%

Summary

AxoGen beats Beta Bionics on 11 of the 15 factors compared between the two stocks.

How does Beta Bionics compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and Beta Bionics (NASDAQ:BBNX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

37.9% of Butterfly Network shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by insiders. Comparatively, 5.3% of Beta Bionics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Butterfly Network has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.13, indicating that its share price is 213% more volatile than the broader market.

In the previous week, Beta Bionics had 3 more articles in the media than Butterfly Network. MarketBeat recorded 8 mentions for Beta Bionics and 5 mentions for Butterfly Network. Butterfly Network's average media sentiment score of 1.11 beat Beta Bionics' score of 0.27 indicating that Butterfly Network is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beta Bionics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beta Bionics has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	24.70	-$77.06M	-$0.29	N/A
Beta Bionics	$100.25M	8.68	-$73.20M	-$1.65	N/A

Beta Bionics has a net margin of -61.31% compared to Butterfly Network's net margin of -66.74%. Beta Bionics' return on equity of -26.30% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-66.74%	-33.99%	-22.96%
Beta Bionics	-61.31%	-26.30%	-23.25%

Butterfly Network currently has a consensus price target of $5.56, indicating a potential downside of 38.57%. Beta Bionics has a consensus price target of $20.10, indicating a potential upside of 3.93%. Given Beta Bionics' stronger consensus rating and higher possible upside, analysts plainly believe Beta Bionics is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Beta Bionics beats Butterfly Network on 10 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to AtriCure?

Beta Bionics (NASDAQ:BBNX) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Beta Bionics has a beta of 3.13, suggesting that its stock price is 213% more volatile than the broader market. Comparatively, AtriCure has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Beta Bionics presently has a consensus price target of $20.10, suggesting a potential upside of 3.93%. AtriCure has a consensus price target of $48.63, suggesting a potential downside of 0.11%. Given Beta Bionics' higher probable upside, research analysts plainly believe Beta Bionics is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
AtriCure	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.91

AtriCure has a net margin of 1.85% compared to Beta Bionics' net margin of -61.31%. AtriCure's return on equity of 2.34% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-61.31%	-26.30%	-23.25%
AtriCure	1.85%	2.34%	1.77%

AtriCure has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	8.68	-$73.20M	-$1.65	N/A
AtriCure	$534.53M	4.63	-$11.45M	$0.21	231.81

In the previous week, AtriCure had 4 more articles in the media than Beta Bionics. MarketBeat recorded 12 mentions for AtriCure and 8 mentions for Beta Bionics. AtriCure's average media sentiment score of 1.31 beat Beta Bionics' score of 0.27 indicating that AtriCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AtriCure	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of AtriCure shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by insiders. Comparatively, 4.0% of AtriCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

AtriCure beats Beta Bionics on 12 of the 17 factors compared between the two stocks.

Get Beta Bionics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBNX vs. The Competition

Export

Metric	Beta Bionics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$887.65M	$5.95B	$7.35B	$12.72B
Dividend Yield	N/A	1.74%	2.53%	10.79%
P/E Ratio	-11.72	26.05	271.01	24.14
Price / Sales	8.68	70.33	636.41	102.23
Price / Cash	N/A	33.27	78.57	53.12
Price / Book	3.39	6.27	13.14	6.25
Net Income	-$73.20M	$149.30M	$3.46B	$347.86M
7 Day Performance	-3.35%	0.25%	1.52%	0.98%
1 Month Performance	22.02%	9.16%	8.81%	5.24%
1 Year Performance	5.51%	6.87%	26.07%	17.04%

Beta Bionics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
BBNX Beta Bionics	1.4285 of 5 stars	$19.34 -2.0%	$20.10 +3.9%	+10.8%	$887.65M	$100.25M	N/A	294
PLSE Pulse Biosciences	1.5946 of 5 stars	$50.42 +5.4%	$45.25 -10.3%	+197.1%	$3.31B	$350K	N/A	140
TMDX TransMedics Group	4.4155 of 5 stars	$94.77 +4.3%	$124.18 +31.0%	-18.6%	$3.14B	$605.49M	24.36	210
AXGN AxoGen	2.3043 of 5 stars	$50.40 +8.5%	$51.00 +1.2%	+237.6%	$2.50B	$225.21M	N/A	450
BFLY Butterfly Network	1.6563 of 5 stars	$9.50 +3.6%	$5.56 -41.4%	+482.3%	$2.44B	$97.61M	N/A	460

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBNX) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beta Bionics (BBNX) Competitors

BBNX vs. PLSE, TMDX, AXGN, BFLY, and ATRC

How does Beta Bionics compare to Pulse Biosciences?

Summary

How does Beta Bionics compare to TransMedics Group?

Summary

How does Beta Bionics compare to AxoGen?

Summary

How does Beta Bionics compare to Butterfly Network?

Summary

How does Beta Bionics compare to AtriCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Beta Bionics (BBNX) Competitors

BBNX vs. PLSE, TMDX, AXGN, BFLY, and ATRC

How does Beta Bionics compare to Pulse Biosciences?

Is BBNX or PLSE more profitable?

Which has higher valuation and earnings, BBNX or PLSE?

Which has more risk and volatility, BBNX or PLSE?

Do analysts recommend BBNX or PLSE?

Does the media favor BBNX or PLSE?

Do institutionals and insiders hold more shares of BBNX or PLSE?

Summary

How does Beta Bionics compare to TransMedics Group?

Does the media refer more to TMDX or BBNX?

Do analysts prefer TMDX or BBNX?

Is TMDX or BBNX more profitable?

Which has more risk and volatility, TMDX or BBNX?

Which has higher valuation & earnings, TMDX or BBNX?

Do insiders and institutionals hold more shares of TMDX or BBNX?

Summary

How does Beta Bionics compare to AxoGen?

Which has more risk and volatility, BBNX or AXGN?

Which has better valuation and earnings, BBNX or AXGN?

Do analysts rate BBNX or AXGN?

Does the media prefer BBNX or AXGN?

Do insiders & institutionals believe in BBNX or AXGN?

Is BBNX or AXGN more profitable?

Summary

How does Beta Bionics compare to Butterfly Network?

Do institutionals & insiders have more ownership in BFLY or BBNX?

Which has more risk & volatility, BFLY or BBNX?

Does the media refer more to BFLY or BBNX?

Which has better earnings and valuation, BFLY or BBNX?

Is BFLY or BBNX more profitable?

Do analysts recommend BFLY or BBNX?

Summary

How does Beta Bionics compare to AtriCure?

Which has more volatility and risk, BBNX or ATRC?

Do analysts prefer BBNX or ATRC?

Is BBNX or ATRC more profitable?

Which has preferable earnings & valuation, BBNX or ATRC?

Does the media prefer BBNX or ATRC?

Do institutionals & insiders hold more shares of BBNX or ATRC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools